Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
06/2005
06/02/2005US20050119486 Diamine derivatives
06/02/2005US20050119333 Compositions comprising ether compounds and pharmaceutical uses therefor
06/02/2005US20050119327 1-benzyl-5-[(3-methylphenyl)amino]-3-phenyl-1H-indole-2-carboxylic acid; plasminogen activator inhibitor (PAI-1) inhibitor; fibrinolytic system disorder; atrial fibrillation, pulmonary and renal fibrosis, Alzheimer's disease; anticarcinogenic, antiischemic, anticoagulant, antidiabetic
06/02/2005US20050119326 Substituted aryloximes
06/02/2005US20050119320 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
06/02/2005US20050119316 Semicarbazide derivatives and the use thereof as antithrombotics
06/02/2005US20050119267 Diazabicyclo alkane derivatives with nk1 antagonistic activity
06/02/2005US20050119259 Synergistic mixture of anticoagulant and antiarrhythmia agents
06/02/2005US20050119223 Injectable solution containing a shark-derived chondroitin sulfate iron colloid
06/02/2005US20050119190 Anticoagulants; cardiovascular disorders; thrombosis
06/02/2005US20050119170 Therapy for anaphylactic shock
06/02/2005US20050118715 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
06/02/2005US20050118684 Recombinant antihemophilic factor for use as tool in treatment hemophilia
06/02/2005US20050118562 Methods for minimizing spasticity in blood vessel grafts
06/02/2005US20050118160 Inhibits delayed vascular rejection; makes organs less vulnerable to rejection after transplantation
06/02/2005US20050118156 Storage-stable fibrin sealant
06/02/2005US20050118150 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine
06/02/2005DE10352602A1 Kosmetisches oder therapeutisches Kombinationspräparat Cosmetic or therapeutic combination product
06/02/2005CA2540986A1 Therapeutic use of factor xi
06/01/2005EP1535929A2 Megakaryocyte stimulating factors
06/01/2005EP1535512A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARa GENE TRANSFERRED THEREINTO AND USE THEREOF
06/01/2005EP1534847A1 Retroviral vector and stable packaging cell lines
06/01/2005EP1534725A2 Compounds and methods for inhibiting selectin-mediated function
06/01/2005EP1534707A1 Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
06/01/2005EP1534687A1 Pyrimidine compounds
06/01/2005EP1534668A1 Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
06/01/2005EP1534666A1 Compounds for modulating the glycolosis enzyme complex and/or transaminase complex
06/01/2005EP1534663A1 N-bridged selective androgen receptor modulators and methods of use thereof
06/01/2005EP1534391A1 Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
06/01/2005EP1534390A2 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- 1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
06/01/2005EP1534290A2 Novel inhibitors of kinases
06/01/2005EP1534289A1 Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
06/01/2005EP1534277A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
06/01/2005EP1534275A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
06/01/2005EP1534251A1 Process for the preparation of pharmaceutical microcapsules with enhanced taste-masking and high dissolution rate
06/01/2005EP1534250A2 Electrospun amorphous pharmaceutical compositions
06/01/2005EP1448794A4 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
06/01/2005EP1423002A4 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent
06/01/2005EP1404330B1 Substituted 8-arylquinoline pde4 inhibitors
06/01/2005EP1345902B1 Substituted heterocyclo-norbornylamine derivatives, method for producing the same, their use as medicament or diagnostic agent and medicament containing the same
06/01/2005EP1254136A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF
06/01/2005EP1233951B1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
06/01/2005EP1178977B1 Ion channel modulating agents
06/01/2005EP1100878B1 Process for producing genetically modified cd34-negative adherently growing haematopoietic stem cells
06/01/2005EP1062210B1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
06/01/2005EP0991625B1 Inhibitors of factor xa with a neutral p1 specificity group
06/01/2005EP0873110B1 Improved hemostatic composition for treating gingival area
06/01/2005CN1622995A Receptor nucleic acids and polypeptides
06/01/2005CN1622827A Thrombin derived peptides for promoting cardiac tissue repair
06/01/2005CN1622820A Therapeutic cream for dermatitis
06/01/2005CN1622818A Therapeutic lotion for dermatitis
06/01/2005CN1622816A Composition and method for augmenting kidney function
06/01/2005CN1622813A Drug I draparinux for treating and secondary prophylaxis of vein thrombo embolism of deep vien thrombus patient
06/01/2005CN1621083A Improvement of method for preparing healthy qi strengthening, astragalus root and glossy privet fruit containing medicine
06/01/2005CN1204250C Method for producing cumic(natto) kinase
06/01/2005CN1204143C Crystalline forms of EtO2C-CH2-(R)Cgl-Aze-Pab-OH
06/01/2005CN1203899C Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy
06/01/2005CN1203873C Medicine for treating epistaxis
06/01/2005CN1203852C Valdecoxib compositions
05/2005
05/31/2005US6900344 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
05/31/2005US6900336 8-aza-11-deoxy prostaglandin analogues
05/31/2005US6900319 Carbo- and heterocyclic amidines
05/31/2005US6900231 Aminopyridyl-substituted phenyl acetamides as protease inhibitors
05/31/2005US6900229 Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide
05/31/2005US6900216 Psychological disorders; antidepressants; brain diosrders; anticonvulsants
05/31/2005US6900200 Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
05/31/2005US6900043 Phosphatases which activate map kinase pathways
05/31/2005US6900008 Methods and formulations for minimizing spasticity in blood vessel grafts
05/31/2005US6899879 Method for treating an IgE-mediated disease in a patient using anti-CD40 monoclonal antibodies
05/31/2005US6899723 Transcutaneous photodynamic treatment of targeted cells
05/26/2005WO2005046623A1 Combined cosmetic or therapeutic preparation
05/26/2005WO2005030785A3 Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therapeutics
05/26/2005US20050113565 Pegylated factor VII glycoforms
05/26/2005US20050113439 Substituted pyrrole-indoles
05/26/2005US20050113436 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione; treating fibrinolytic disorders, vein thrombosis and coronary heart disease, and pulmonary fibrosis
05/26/2005US20050113428 2-{3,5-bis[(3-chlorobenzyl)oxy]benzyl}-1,2,4-oxadiazolidine-3,5-dione to treat disorders associated with elevated PAI-1(Plasminogen activator inhibitor) levels
05/26/2005US20050113406 Blood platelet aggregation inhibiting and antithrombotic effect; uniform crystal form; reproducable industrial scale manufacture
05/26/2005US20050113402 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
05/26/2005US20050113377 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors
05/26/2005US20050113370 Therapeutic substituted indazole derivatives
05/26/2005US20050113358 Enzyme inhibitors for erectile dysfunction and sexual disorders
05/26/2005US20050113309 Useful as thrombin inhibitors
05/26/2005US20050113299 Protein a compositions and methods of use
05/26/2005US20050113289 Conjugate of hemoglobin covalently joined to a polysaccharide; for use as synthetic blood; preventing hemorrhagic shock
05/26/2005US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/26/2005US20050112565 Proteases
05/26/2005US20050112206 Mixture of drug, aminoacrylate polymer and acid
05/26/2005US20050112114 Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
05/26/2005CA2543806A1 Combined cosmetic or therapeutic preparation
05/25/2005EP1533374A1 Novel peptides having camp producing activity
05/25/2005EP1533318A1 Prodrugs of thrombin inhibitors
05/25/2005EP1532242A2 Methods for preparing purified prostaglandin e synthase
05/25/2005EP1532238A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/25/2005EP1532133A1 Nf-:b inhibitors
05/25/2005EP1532111A1 2,5-disubstituted 3-mercaptopentanoic acid
05/25/2005EP1531879A1 Use of organic compounds
05/25/2005EP1531856A1 Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
05/25/2005EP1531847A2 Pharmaceutical formulation
05/25/2005EP1531817A1 Glycinamide derivatives as raf-kinase inhibitors
05/25/2005EP1531806A2 Use of thio-oxindole derivatives in treatment of hormone-related conditions
1 ... 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 ... 671